GoldenGolden
Advanced Search
BillionToOne

BillionToOne

A diagnostic DNA testing company using quantified biological data.

Founded in 2016 by , , and , BillionToOne is a DNA diagnostic company originating from 's . It is located in , and uses diagnostic testing that quantifies molecular level bodily changes.

COVID-19 Response

BillionToOne received emergency use authorization from the (FDA) in 2020, for its SARS-CoV-2 test that removes the process of () extraction, a time-consuming step in testing. BillionToOne developed a COVID-19 testing method called the qSanger-COVID-19 assay. It uses different instrument sets and chemicals than other methods that were applied in 2020. BillionToOne partnered with SwiftBiosciences to manufacture the COVID-19 assay kits and began international distribution in May of 2020.

qSanger

qSangerTM technology is a patent-pending test developed by BillionToOne that works to detect viral RNA. It is based on the technology in Sanger sequencing, a DNA testing method that determines the nucleotide sequence in DNA molecules, also known as the "chain termination method."

Timeline

July 12, 2021
BillionToOne closes $55,000,000 Series B Funding round led by Hummingbird Ventures and Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.
July 12, 2021
BillionToOne raises a $55,000,000 series B round.
March 2020
BillionToOne raises a $15,000,000 series A round from 500 Startups Istanbul, Andrea Dusi, Civilization Ventures, Friále, HOF Capital, Hummingbird Ventures, Libertus Capital, NeoTribe Ventures, Pacific 8 Ventures and Y Combinator.
March 13, 2019
BillionToOne raises a $15,000,000 series A round from 500 Startups, Civilization Ventures, Fifty Years, HOF Capital, Hummingbird Ventures, NeoTribe Ventures and Y Combinator.
September 15, 2017
BillionToOne raises a $2,400,000 seed round from Friále, NewDo Venture, UpHonest Capital and Wei Guo.
August 2017
BillionToOne raises a $120,000 seed round from Y Combinator.
January 2016
BillionToOne was founded by Dave Tsao, Oguzhan Atay and Sukrit Silas.

Funding rounds

People

Name
Role
LinkedIn

Ashley Patterson

Senior Account Executive

Chenier Caoile

Senior Clinical Laboratory Scientist

Chris Patrick Maningo

Senior Client Services Associate

Devon Chandler-Brown

Senior Scientist

Doktor Gurson

Advisor/ Investor

Nancy Johnson, MT (ASPC)

Vice President of Sales & Commercial Operations

Oguzhan Atay, PhD

Co-Founder & CEO

Further reading

Title
Author
Link
Type
Date

BillionToOne Announces Groundbreaking New COVID-19 Test Unlocking One Million Daily Tests

PR Newswire

Web

April 7, 2020

BillionToOne, Inc. and Eluthia Launch UNITYTM Test, the First Non-Invasive Prenatal Test for Cystic Fibrosis, Spinal Muscular Atrophy and Hemoglobinopathies in Germany, Austria, Switzerland and the Netherlands

BillionToOne, Inc

Web

October 31, 2019

BillionToOne, Inc., announced today that it has closed its follow-on Series A+ funding round of $15 million

BillionToOne, Inc

Web

March 10, 2020

Diagnostics firm claims to have potential for 1 million COVID-19 tests per day

Web

April 15, 2020

Documentaries, videos and podcasts

Title
Date
Link

BillionToOne Molecular Counting Technology (2019)

January 17, 2019

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
July 12, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.